© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
Metabolism of bradykinin by the rat coronary vascular bed
Faculté de pharmacie, Université de Montréal, C.P. 6128 Succ. Centre-ville, Montréal, (Québec), Canada, H3C 3J7
* Corresponding author. Tel.: +1 (514) 343-5909; Fax: +1 (514) 343-2102.
Objective: To study the metabolism of bradykinin (BK) after a single passage through the coronary bed in isolated Langendorff rat hearts. Methods: BK was infused into the aortic flow line to obtain a final concentration of 10 nM, and the coronary effluent was collected to quantify BK and des-Arg9-BK by competitive enzyme immunoassay. The nature of immunoreactive material was confirmed by immunograms after HPLC separation. The experiments were performed with hearts perfused at either one of the following coronary flow rates: 1, 5 or 10 ml/min. Results: BK recovery without inhibitors was 86.3±2.9, 60.8±6.3, and 29.6±6.8% at 10, 5, and 1 ml/min, respectively. The Vmax/Km ratios at these coronary flow rates were 2.19±0.72, 4.81±0.64, and 2.59±0.33 min–1 g–1, respectively. The angiotensin-converting enzyme (ACE) inhibitor, enalaprilat (130 nM), reduced BK degradation at all flow rates. Inhibition of neutral endopeptidase with retrothiorphan (25 nM) had no effect on BK degradation. However, the combined treatment with enalaprilat and retrothiorphan reduced BK degradation to lower values than enalaprilat alone. The effect of enzyme inhibitors on BK recovery was inversely related to coronary flow: inhibiting BK degradation markedly increased BK recovery at 1 ml/min, but had no effect at 10 ml/min. The kininase I metabolite of BK, des-Arg9-BK, could not be detected under these experimental conditions. Conclusions: ACE is the major enzyme responsible for BK degradation during a single passage through the coronary bed. Neutral endopeptidase contributes to BK degradation only when ACE activity is impaired. The effect of enzyme inhibitors on the coronary concentration of BK is highly dependent on coronary flow rate.
KEYWORDS Bradykinin; Metabolism; Angiotensin-converting enzyme; Neutral endopeptidase; Coronary bed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Boix, C. Roe, L. Rosenborg, and S. Knardahl Kinin peptides in human trapezius muscle during sustained isometric contraction and their relation to pain J Appl Physiol, February 1, 2005; 98(2): 534 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition Hypertension, December 1, 2004; 44(6): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Blais Jr., D. Fortin, J.-L. Rouleau, G. Molinaro, and A. Adam Protective Effect of Omapatrilat, a Vasopeptidase Inhibitor, on the Metabolism of Bradykinin in Normal and Failing Human Hearts J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 621 - 626. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Raut, J.-L. Rouleau, C. Blais Jr., H. Gosselin, G. Molinaro, M. G. Sirois, Y. Lepage, P. Crine, and A. Adam Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11 Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1769 - H1779. [Abstract] [Full Text] [PDF]
|
|